Takeshita, Saki
Nishioka, Yuichi
Tamaki, Yuko
Kamitani, Fumika
Mohri, Takako
Nakajima, Hiroki
Kurematsu, Yukako
Okada, Sadanori
Myojin, Tomoya
Noda, Tatsuya
Imamura, Tomoaki
Takahashi, Yutaka
Funding for this research was provided by:
Novo Nordisk Pharma
Japan Society for the Promotion of Science (JP18K17390, JP21K10474, JP21K10451, JP18H04126)
Health Science and Labour Research Grants (21IA1006)
Article History
Received: 8 September 2023
Accepted: 2 January 2024
First Online: 9 January 2024
Declarations
:
: The data used in this study were anonymized before provision to the authors. Therefore, the patient informed consent procedure is waived and the experimental protocol is approved by the Nara Medical University Ethics Committee (approval number: 1123–7). We confirm that all methods were performed in accordance with the relevant guidelines and regulations.
: Not applicable.
: Y.N. received consultant fees from Novo Nordisk and speaker fees from Daiichi Sankyo and Sanofi. F.K. received speaker fees from Dainippon Sumitomo, Sanofi. Ta.M. received speaker fees from Dainippon Sumitomo, MSD, and Eli Lilly. S.O. received non-purpose research grants from Japanese Red Cross Society; speaker fees from Taisho, Mitsubishi Tanabe, Dainippon Sumitomo, Eli Lilly, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Novo Nordisk, Mochida, Kyowa Kirin, Terumo, and Ono. Y.T. received consultant fees from Novo Nordisk, Otsuka, and Recordati and speaker fees from Novo Nordisk, Sumitomo Dainippon, Eli Lilly, Ono, Novartis, Nippon Boehringer Ingelheim, AstraZeneca, and Kyowa Kirin. All the other authors declare that they have no competing interests.